We hypothesize that a therapeutic strategy based on the blockade of PD(L)1, as well as other receptors also involved in immuno-modulation, such as LAG3, together with the pharmacological inhibition of BRAF, could help to improve current treatments against BRAF-mutated CRC tumors. The gene discussed is LAG3; the disease is colorectal carcinoma.